RenalGuard Solutions, a pioneering medical device company focused on protecting patients from acute kidney injury (AKI), stated that the KIDNEY clinical trial confirmed RenalGuard Therapy protects at-risk patients undergoing cardiac surgery with cardiopulmonary bypass (CPB) from Acute Kidney Injury (AKI). Results of the 220 patient, randomized trial comparing automated diuresis technology to standard hydration were published, in the European Journal of Cardio-Thoracic Surgery. The study was conducted by investigators at the Heart and Lung Centre, New Cross Hospital in Wolverhampton, United Kingdom.
In the KIDNEY trial, patients at-risk for AKI were randomized, into either a RenalGuard Therapy treatment group or a control group managed with standard-of-care hydration. Risk factors for AKI included a history of diabetes and or anaemia; estimated Glomerular Filtration Rate (eGFR) < 60 ml/min/1.72m2; anticipated cardiac surgery time >120 minutes and Log EuroScore > 5. AKI was defined, as a rise in serum creatinine greater than 50% in the days post-procedure.
The RenalGuard group’s post-operative AKI rates were significantly lower than the control group’s, 10% vs 20.9%. As well, the mean volumes of urine produced during surgery (2337 + 896 ml vs 766 + 557 ml) and within 24 hours post-op in ICU (3297 + 1298 ml vs 2053 + 802 ml) were significantly higher in the RenalGuard group. Median ICU stays were similar for the two groups.
The investigators led by Dr. Heyman Luckraz concluded that: “In patients at risk for AKI who had cardiac surgery with CPB, the RG system significantly reduced the incidence of AKI and can be used safely and reproducibly.”
RenalGuard Therapy entails the use of RenalGuard’s automated fluid management system with a physician-prescribed loop diuretic to induce high urine output rates, which protect against AKI. Used with more than 30,000 patients, the automated fluid management system is designed to measure urine output and replace it in real-time with an equal volume of sterile saline.
Jim Dillon, President and Chief Executive Officer, RenalGuard Solutions said: “We are very gratified by the results of this comprehensive study of RenalGuard in the cardiac surgery setting, which show this technology’s promise in this area as a means to protect a very high-risk population from cardiac surgery-associated AKI. We look forward to further exploring the use of RenalGuard to reduce the incidence of AKI in this patient population.”